Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Shin Nippon Biomedical Laboratories's pretax income for the
three
months ended in Mar. 2026 was $22.0 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2026 was $46.6 Mil.
Shin Nippon Biomedical Laboratories's pretax margin was 30.87%.
During the past 13 years, Shin Nippon Biomedical Laboratories's highest Pretax Margin was 46.11%. The lowest was -9.08%. And the median was 20.12%.
During the past 13 years, Shin Nippon Biomedical Laboratories's highest Pretax Margin was 46.11%. The lowest was -9.08%. And the median was 20.12%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories Pre-Tax Income Related Terms
Shin Nippon Biomedical Laboratories Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories Pre-Tax Income Chart
SBLOF vs TMO, DHR, IDXX: Pre-Tax Income Comparison
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories Pre-Tax Income vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $46.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories (SBLOF) has a Pre-Tax Income of $46.6 Mil as of Mar. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Shin Nippon Biomedical Laboratories and its competitors.
Is Shin Nippon Biomedical Laboratories' Pre-Tax Income too high?
Shin Nippon Biomedical Laboratories' current Pre-Tax Income is $46.6 Mil. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Pre-Tax Income compare to TMO and DHR?
Shin Nippon Biomedical Laboratories' Pre-Tax Income of $46.6 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Medical Diagnostics & Research company?
A good Pre-Tax Income depends on the Medical Diagnostics & Research industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Shin Nippon Biomedical Laboratories and its competitors. Shin Nippon Biomedical Laboratories's current Pre-Tax Income is $46.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current Pre-Tax Income of $46.6 Mil. The stock's GF Value™ is $11.13, compared to a current price of $9.16 — trading 17.7% below its estimated fair value. The current Pre-Tax Income is $46.6 Mil. Shin Nippon Biomedical Laboratories' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current Pre-Tax Income is $46.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 17.7% below its estimated GF Value™ of $11.13.
Key valuation signals for SBLOF:
Pre-Tax Income: $46.6 Mil
GF Value™: $11.13 vs. price of $9.16 (17.7% below fair value)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
79GF Score
Get the complete analysis for SBLOF
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
